Pricing Log in Create free account
Saturday 31 October 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,415.16 41.46 +3.02%
Market cap
$1.29T
P/E
47.5×
Fwd P/E
36.7×
Dividend yield
0.47%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Eli Lilly and Company (LLY) Shares outstanding

Alert me on Shares outstanding

Eli Lilly and Company's shares outstanding at the end of fiscal 2025 was $899.3M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $893.7M. Over the past ten years it has ranged from $899.3M (fiscal 2025) to $1.1B (fiscal 2015) — the current reading is the lowest in ten years. Eli Lilly and Company ranks 12th of 20 Drug Manufacturers General companies by shares outstanding.

Shares outstanding, annual

Embed this chart

Annual newest first

Period Shares outstanding Change
FY2025 $899.3M (0.53%)
FY2024 $904.1M 0.09%
FY2023 $903.3M (0.15%)
FY2022 $904.6M (0.77%)
FY2021 $911.7M (0.09%)
FY2020 $912.5M (2.48%)
FY2019 $935.7M (9.48%)
FY2018 $1.0B (1.74%)
FY2017 $1.1B (0.92%)
FY2016 $1.1B (0.37%)

Quarterly newest first

Period Shares outstanding Change
Jun 2026 $893.7M (0.25%)
Mar 2026 $895.9M (0.38%)
Dec 2025 $899.3M 0.06%
Sep 2025 $898.8M (0.11%)
42 more quarters

Against its own ten years

Low $899.3M High $1.1B
Ten-year median $912.5M
Current reading's percentile 9

Shares outstanding against peers

Company Shares outstanding
PFE Pfizer Inc. compare $5.7B
MRK Merck & Co., Inc. compare $2.5B
JNJ Johnson & Johnson compare $2.4B
NVS Novartis AG compare $1.9B
ABBV AbbVie Inc. compare $1.8B
AZN AstraZeneca PLC compare $1.6B
GILD Gilead Sciences, Inc. compare $1.2B
LLY Eli Lilly and Company $893.7M
AMGN Amgen Inc. compare $544.0M

What Shares outstanding is

Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.

Reported line item

The full definition of Shares outstanding →

More on LLY